stella
beta
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) — Stella
Recruiting
Back to Hepatocellular Carcinoma trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Trial locations
(1 site)
China
Mian Xi, Guangzhou, Guangdong
View full record on ClinicalTrials.gov